CompletedNCT00567203

A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

This study evaluated the safety and effectiveness of PF-3463275 for people with schizophrenia.

Medication studyAges 18–55United States

The study in practice

Understand this study

This study evaluated the safety and effectiveness of PF-3463275 for people with schizophrenia.

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations: Glendale and 1 more locationSee all locations and recruitment
Study phase: Phase 1

Study clarity

Study start dateNovember 2007

Recruitment status: Completed
Enrollment listed in the registry: 36
Sponsor: Pfizer
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: United States
Age range: From 18 Years to 55 Years
Official registry ID: NCT00567203
Official title: Show the full official title
A Phase 1B Inpatient, Randomized, Double-Blind, Placebo-Controlled, Crossover Study Of The Safety And Efficacy Of Two Fixed Doses Of PF-3463275 In Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

Completed

Glendale · Willingboro

FAQ

What did researchers investigate?

This study evaluated the safety and effectiveness of PF-3463275 for people with schizophrenia.

Who is behind this study?

The study sponsor is Pfizer.

Did this study involve medication?

Yes. The study involved medication, including PF-3463275 and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.